Personal information

Websites & social links

larssteggink.nl

Other IDs

Scopus Author ID: 55827091900

Countries

Netherlands

Activities

Collapse all

Employment (3)

Maastricht University Medical Centre: Maastricht, NL

2024 to present | Medical Oncologist (Medical Oncology)
Employment
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Erasmus University Medical Center: Rotterdam, NL

2022 to 2024 | Resident (Medical Oncology)
Employment
Source: Self-asserted source
dr. L.C. (Lars) Steggink

University Medical Center Groningen: Groningen, Groningen, NL

2016 to 2022 | PhD student / physician-scientist (Medical Oncology)
Employment
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Works (17)

Long-term outcome and treatment-related toxicity in patients with breast and testicular cancer

2022 | Dissertation or Thesis
HANDLE: 11370/54be20ed-8496-49df-9884-fc1cf4e7c75c
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors

Breast Cancer Research and Treatment
2022-12 | Journal article
DOI: 10.1007/s10549-022-06714-0
Contributors: Annemiek van Ommen-Nijhof; Judy N. Jacobse; Lars C. Steggink; Joop D. Lefrandt; Jourik A. Gietema; Flora E. van Leeuwen; Michael Schaapveld; Gabe S. Sonke
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Langetermijneffecten van behandelingen van borstkanker en zaadbalkanker.

Ned Tijdschr Oncol.
2022-08 | Journal article
Contributors: dr. L.C. (Lars) Steggink
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors

JACC: CardioOncology
2022-06 | Journal article | Author
DOI: 10.1016/j.jaccao.2022.02.007
SOURCE-WORK-ID:

e73e82a6-9d9b-4c6b-af09-3cc619411a16

EID:

2-s2.0-85132318631

PMID: 35818555
Contributors: Willeke R. Naaktgeboren; Wim G. Groen; Judy N. Jacobse; dr. L.C. (Lars) Steggink; Annemiek M.E. Walenkamp; Wim H. van Harten; Martijn M. Stuiver; Neil K. Aaronson; Berthe M.P. Aleman; Peter van der Meer et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 2)‎

Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.

Journal of Clinical Oncology
2022-06-01 | Conference abstract
DOI: 10.1200/jco.2022.40.16_suppl.541
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Contributors: dr. L.C. (Lars) Steggink
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy

Pharmacogenomics Journal
2021-04 | Journal article | Author
DOI: 10.1038/s41397-020-00191-8
SOURCE-WORK-ID:

dd210a6f-f574-49f2-abdd-85dfc2b56413

PMID: 33011741
EID:

2-s2.0-85091840844
Contributors: dr. L.C. (Lars) Steggink; Hink Boer; Coby Meijer; Joop D Lefrandt; Leon W M M Terstappen; Rudolf S N Fehrmann; Jourik A Gietema
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 2)‎

Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy

British Journal of Cancer
2020-11 | Journal article | Author
DOI: 10.1038/s41416-020-01049-3
SOURCE-WORK-ID:

74375621-dee2-4a09-a71c-085e69ab6ed6

PMID: 32921790
EID:

2-s2.0-85090948666
Contributors: Johannes Stelwagen; Sjoukje Lubberts; dr. L.C. (Lars) Steggink; Gerrie Steursma; Lara M Kruyt; Jan Willem Donkerbroek; Arie M van Roon; Anne I van Gessel; Saskia C van de Zande; Coby Meijer et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 2)‎

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer-Reply

JAMA Oncology
2020-08-01 | Journal article | Author
DOI: 10.1001/jamaoncol.2020.1649
SOURCE-WORK-ID:

6adb9538-81ca-4c7a-9b95-f88017a9c632

PMID: 32496508
EID:

2-s2.0-85086267735
Contributors: Tessa G Steenbruggen; dr. L.C. (Lars) Steggink; Gabe S Sonke
Source: check_circle
EUR & Erasmus MC Research Information Portal

Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years

European Journal of Heart Failure
2020-02 | Journal article | Author
DOI: 10.1002/ejhf.1610
SOURCE-WORK-ID:

88609fea-4ac6-447c-908c-8bd2ae3d58d9

PMID: 31696625
EID:

2-s2.0-85074818028
Contributors: Judy N Jacobse; dr. L.C. (Lars) Steggink; Gabe S Sonke; Michael Schaapveld; Yoran M Hummel; Tessa G Steenbruggen; Joop D Lefrandt; Janine Nuver; Anne P G Crijns; Berthe M P Aleman et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 2)‎

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes 20-Year Follow-up of a Phase 3 Randomized Clinical Trial

JAMA Oncology
2020-01-30 | Journal article | Author
DOI: 10.1001/jamaoncol.2019.6276
SOURCE-WORK-ID:

0cc97eb6-6408-43a0-b783-f6e21418b073

EID:

2-s2.0-85078879524

PMID: 31999296
Contributors: TG Steenbruggen; dr. L.C. (Lars) Steggink; Caroline Seynaeve; JJ van der Hoeven; Maartje Hooning; Agnes Jager; IR Konings; J R Kroep; WM Smit; VC Tjan-Heijnen et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 2)‎

Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients

Andrology
2019-07 | Journal article | Author
DOI: 10.1111/andr.12581
SOURCE-WORK-ID:

74aeb200-84a4-47cd-9279-07bfd9e80008

PMID: 30609309
EID:

2-s2.0-85059514381
Contributors: dr. L.C. (Lars) Steggink; A P van Beek; H Boer; C Meijer; S Lubberts; S F Oosting; I J de Jong; R J van Ginkel; J D Lefrandt; J A Gietema et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 4)‎

Cardiac Function After Radiation Therapy for Breast Cancer

International journal of radiation oncology, biology, physics
2019-06-01 | Journal article | Author
DOI: 10.1016/j.ijrobp.2019.02.003
SOURCE-WORK-ID:

a285d122-fe71-45a8-9ba4-f7bd3aebc286

PMID: 30763659
EID:

2-s2.0-85062806682
Contributors: Veerle A B van den Bogaard; Peter van Luijk; Yoran M Hummel; Peter van der Meer; Ewoud Schuit; Liselotte M Boerman; Saskia W M C Maass; Jan F Nauta; dr. L.C. (Lars) Steggink; Jourik A Gietema et al.
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 4)‎

911P Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy

European Society for Medical Oncology 2018 meeting
2018 | Conference poster
DOI: 10.1093/annonc/mdy283.120
Source: Self-asserted source
dr. L.C. (Lars) Steggink

187O High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with ≥4 involved axillary lymph nodes (ALN)

European Society for Medical Oncology 2018 meeting
2018-10-01 | Conference abstract
DOI: 10.1093/annonc/mdy270.184
Source: Self-asserted source
dr. L.C. (Lars) Steggink

Cardio-Oncology

Clinical Pharmacology and Therapeutics
2017-04 | Journal article | Author
DOI: 10.1002/cpt.614
SOURCE-WORK-ID:

8306239f-463f-4096-9405-a6784a695d78

PMID: 28073142
EID:

2-s2.0-85013213196
Contributors: J Tromp; dr. L.C. (Lars) Steggink; D J Van Veldhuisen; J A Gietema; P van der Meer
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 4)‎

Survival in anaplastic thyroid cancer in relation to pre-existing goiter

American Journal of Surgery
2015-06 | Journal article | Author
DOI: 10.1016/j.amjsurg.2014.06.027
SOURCE-WORK-ID:

b855356f-2c0b-438b-9135-466f081b0447

PMID: 25242682
EID:

2-s2.0-84930079395
Contributors: dr. L.C. (Lars) Steggink; Boukje A C van Dijk; Thera P Links; John Th M Plukker
Source: check_circle
EUR & Erasmus MC Research Information Portal
grade
Preferred source (of 5)‎

[A woman with skin abnormalities and muscle weakness].

2013 | Journal article
PMID:

23890170
Contributors: Steggink LC; Hettema ME; Delsing CE
Source: Self-asserted source
dr. L.C. (Lars) Steggink via Europe PubMed Central
grade
Preferred source (of 3)‎
How many people are using ORCID?